Oncoinvent ASA ONCIN

Oncoinvent ASA (STU:7BG) advances lead candidate Radspherin with strong recruitment and FDA fast track designation, while preparing for a larger phase 3 trial.

Oncoinvent, a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces the publication of clinical dosimetry data for Radspherin® in the Journal of Nuclear Medicine, one of the leading peer-reviewed journals in the field.

Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that its ongoing Phase 2 trial of Radspherin® in patients with peritoneal metastases from ovarian cancer has reached the 50% patient recruitment milestone.

Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced positive final 24-month follow-up results from its Phase 1 clinical trial (RAD-18-001) evaluating Radspherin® in patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis. Radspherin®, direct intraperitoneal targeting with the alpha-emitter radium-224, aims to eliminate post-surgery micro-metastases and thereby prevent or delay peritoneal